|
ÆòÅüº¸ðº´¿ø |
ÆòÅüº¸ðº´¿ø ¾à»ç´Ô ¸ðÁý
°æ±â ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
°æ·Â¹«°ü |
ä¿ë½Ã |
05.25 |
|
|
Çѱ¹¿¥¿¡½ºµð ÁÖ½Äȸ»ç |
[Çѱ¹MSD] MSL-ID/Vaccine
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
08.13 |
|
|
ºñºê¶ó¿îÄÚ¸®¾Æ |
ºñºê¶ó¿îÄÚ¸®¾Æ ÀÇ·á±â±â/Á¦¾à ÀÇ·á±â±â/Á¦¾à ¾à»ç ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
°æ·Â¹«°ü |
ä¿ë½Ã |
08.05 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
Medcial Service Specialist ¸ðÁý
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
3³â¡è |
ä¿ë½Ã |
05.17 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
Medical Information Associate(À°¾ÆÈÞÁ÷´ëü±Ù¹«)
¼¿ï Áß±¸ | Çз¹«°ü |
¾à»ç/ÇѾà»ç |
°æ·Â¹«°ü |
ä¿ë½Ã |
03.31 |
|
|
Çѱ¹MSD ÁÖ½Äȸ»ç |
ID/Vaccine MSL ¸ðÁý
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Çмú/±³À°/»ó´ã |
2³â¡è |
ä¿ë½Ã |
03.11 |
|
|
Çѱ¹MSD µ¿¹°¾àÇ° |
Çѱ¹MSD µ¿¹°¾àÇ° °ü¸®¾à»ç ¸ðÁý(À°¾ÆÈÞÁ÷´ëü±Ù¹«)
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
°æ·Â¹«°ü |
ä¿ë½Ã |
03.04 |
|
|
½ÎÀÌÁ¨ÄÚ¸®¾Æ(ÁÖ) |
½ÎÀÌÁ¨ÄÚ¸®¾Æ(ÁÖ) ¼öÀÔ°ü¸® ¾à»ç(ÆÄÆ®) ¸ðÁý
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
3³â¡è |
ä¿ë½Ã |
03.03 |
|
|
Çѱ¹Organon |
Çѱ¹Organon Market Access ´ã´çÀÚ ¸ðÁý
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
1³â¡è |
ä¿ë½Ã |
01.15 |
|
|
Çѱ¹Organon |
Çѱ¹Organon-Market Access Specialist 1¸í ¸ðÁý
¼¿ï Á¾·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
12.04 |
|
|
¿î¾ÏÇÑÀÇ¿ø |
ÃæºÏ ûÁֽà <<¿î¾ÏÇÑÀÇ¿ø>> ÇѾà»ç ¸ðÁýÇÕ´Ï´Ù.
ÃæºÏ ûÁֽà »ó´ç±¸ | Çз¹«°ü |
¾à»ç/ÇѾà»ç |
°æ·Â¹«°ü |
ä¿ë½Ã |
11.20 |
|
|
½«Ä¿ÄÚ¸®¾Æ |
Healthcare Quality Management(Pharmacist)
°æ±â ±ºÆ÷½Ã | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
3³â¡è |
ä¿ë½Ã |
05.20 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
Oncology MSL 2¸í ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
10.31 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
Market access(Price&reimburse)specialist ¸ðÁý
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
±¤°í/È«º¸/PR/»çº¸ |
3³â¡è |
ä¿ë½Ã |
10.29 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
RA Specialist 2¸í ä¿ë(»êÈÞ´ëü/½ÅÀÔ°¡´É)
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
°æ·Â¹«°ü |
ä¿ë½Ã |
10.14 |
|